IMRNNasdaqPharmaceutical PreparationsFiscal year ends June 30
Immuron Ltd
Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Sep 24, 2026
$0.96−0.03 (-2.62%)
Close on Oct 19, 2026
Margins
Share of revenue, fiscal years 2015 to 2026
Gross margin
64.5%−0.5 pts over 5 years
Operating margin
-49.9%+5698.6 pts over 5 years
Net margin
-47.7%+5703.9 pts over 5 years
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +5.9% | +62.3% | +121.2% | +22.7% | |
| Gross profit | +4.4% | +56.1% | +120.8% | +21.7% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on assets | – | -50.4% | -31.6% | |
| Current ratio | 4.83 | 22.96 | 7.26 | |
| Interest coverage | -75.0× | -609.0× | -261.7× | |
| Inventory turnover | – | 0.1× | 1.4× | |
| Capex to revenue | 0.4% | 4.5% | 0.1% | |
| Diluted shares | – | – | 297M |
Cash use needs five years of cash flow figures
Immuron does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
3of 8 tests passed in fiscal 2026. Some tests lack the figures they need.
- ProfitableNet income above zero-A$3.68M
- Cash generatingOperating cash flow above zero-A$3.26M
- Return on assets improvedROA up on the prior year-33.5% → -36.3%
- Earnings backed by cashOperating cash flow above net income-A$3.26M vs -A$3.68M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose5.09 → 7.26
- No dilutionShare count did not rise231M → 297M
- Gross margin improvedGross margin up on the prior year65.39% → 64.50%
- More efficientAsset turnover rose0.47 → 0.76